Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
FAK inhibitors in cancer, a patent review – an update on progress36
Malaria transmission blocking compounds: a patent review36
Recent developments of agents targeting Vibrio cholerae : patents and literature data35
Update on mGlu4 modulator patents: 2017 to present34
The role of patent analysis in target selection33
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)31
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities30
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature27
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review26
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)24
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present24
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of MAPK inhibitors (2018 – present)22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
Inhibition of GTPase KRAS G12D : a review of patent literature19
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review18
Small-molecule RNA ligands: a patent review (2018–2024)18
Antiprotozoal drugs: challenges and opportunities18
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)18
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)17
An updated patent review of MALT1 inhibitors (2021–present)17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
A patent review of IDH1 inhibitors (2018-present)16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders15
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)15
Biofilm and bacterial membrane vesicles: recent advances14
A patent and literature review of CDK12 inhibitors14
Antimalarial drugs: what’s new in the patents?14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)13
Dopamine D3 receptor ligands: a patent review (2014–2020)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Are patents important indicators of innovation for Chagas disease treatment?12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
An updated patent review of EZH2 inhibitors (2024–present)12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
The patent review of the biological activity of tropane containing compounds11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An updated patent review of TRPA1 antagonists (2020 – present)11
Correction11
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
0.086456060409546